Ayobami gives Plenary at the 2024 AAAAI: “Pharmacoequity in Eligibility & Access to Biologics in Patients with Asthma”.

Key takeaways include: 1.) Characteristics of trial populations influence eligibility criteria approved by the FDA/regulatory bodies. 2.) Insurance alone does not tell the full story of lower access to biologics in individuals with public insurance or belonging to historically marginalized groups; 3.) There is no ‘perfect’ biologic therapy. We need to match the right patient to the right biologic.